Viking Global Investors, a private equity firm, led a $75m Series C funding round in 4D Molecular Therapeutics, a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution. The round had participation from investors Amzak Health, Casdin Capital, Cystic Fibrosis Foundation, Longevity Vision Fund, MiraeAsset Financial Group, Octagon Investments, QUAD Investment Management, Arrowmark Partners, Berkeley Catalyst Fund, BVF Partners, Pappas Capital & Chiesi Ventures, Perceptive Advisors, Pfizer Ventures, and Ridgeback Capital Investments. "This financing enables 4DMT to advance three product candidates into clinical trials, and to progress our mission of unlocking the full potential of gene therapy for broad populations of patients suffering from both rare and large market diseases. We are privileged to be supported by such high caliber life science investors who share our vision," David Kirn, 4DMT Managing Director, Co-Founder, Chairman and CEO.